CLL Society Honors Innovators in Leukemia and Lymphoma Research
The CLL Society has awarded three researchers for their innovative projects aimed at improving care and outcomes for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, highlighting the importance of integrative medicine, clinical research, and overcoming treatment resistance.
The CLL Society has announced the recipients of its 2025 Research Program awards, recognizing three researchers for their contributions to advancing care for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These awards underscore the society's commitment to funding innovative research that addresses critical gaps in patient care and treatment.
Dr. Nancy Musoke received the Integrative Medicine Award for her study on the effects of curcumin and exercise on CLL/SLL progression and immune function. This research is pivotal as it explores non-pharmacologic interventions that could enhance quality of life and potentially slow disease progression for patients in the early stages of the disease.
The Clinical Scholar Award was granted to Dr. Matthew S. Davids for his work on optimizing glofitamab combination therapy for Richter's transformation, a severe complication of CLL. His research aims to develop more effective and less toxic treatment options, offering hope for patients facing this aggressive disease progression.
Dr. Quinlan Sievers was honored with the Young Investigator Award for his project on discovering and overcoming resistance mechanisms to BTK inhibitors, a promising treatment for CLL/SLL. His work could lead to more durable and personalized therapies for patients who relapse after current treatments.
These awards reflect the CLL Society's dedication to supporting research that can transform the lives of patients. For more information on the research funded by the CLL Society, visit https://cllsociety.org/what-we-fund/.